Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17483508 | 0.78 | SLC6A9 (0.35) | SLC6A9 | |
| SCHEMBL5481123 | 0.73 | MEN1 (0.30) | — | |
| SCHEMBL26206931 | 0.72 | SLC6A9 (0.36) | SLC6A9 | |
| SCHEMBL19075642 | 0.70 | MEN1 (0.30) | — | |
| SCHEMBL19084121 | 0.70 | CHRNB2 (0.36) | — | |
| SCHEMBL18116222 | 0.66 | HSD11B1 (0.43) | — | |
| SCHEMBL14343401 | 0.66 | HSD11B1 (0.43) | — | |
| SCHEMBL5319161 | 0.62 | APLNR (0.33) | APLNR | |
| SCHEMBL14812012 | 0.62 | APLNR (0.33) | APLNR | |
| SCHEMBL19255881 | 0.61 | FFAR3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180362519-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2018-12-20 | — | — | US | disclosed |
| EP-3411371-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | Pfizer Inc (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017134547-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017134547-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362519-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | NGLY1, TEK, TEKT1 | SLC6A9 2323/4885APLNR 338/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | SLC6A9 2323/4885APLNR 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.